Literature DB >> 20345705

GPVI and CLEC-2 in hemostasis and vascular integrity.

S P Watson1, J M J Herbert, A Y Pollitt.   

Abstract

SUMMARY: The glycoprotein VI (GPVI)-FcR gamma-chain complex initiates powerful activation of platelets by the subendothelial matrix proteins collagen and laminin through an immunoreceptor tyrosine-based activation motif (ITAM)-regulated signaling pathway. ITAMs are characterized by two YxxL sequences separated by 6-12 amino acids and are found associated with several classes of immunoglobulin (Ig) and C-type lectin receptors in hematopoietic cells, including Fc receptors. Cross-linking of the Ig GPVI leads to phosphorylation of two conserved tyrosines in the FcR gamma-chain ITAM by Src family tyrosine kinases, followed by binding and activation of the tandem SH2 domain-containing Syk tyrosine kinase and stimulation of a downstream signaling cascade that culminates in activation of phospholipase Cgamma2 (PLCgamma2). In contrast, the C-type lectin receptor CLEC-2 mediates powerful platelet activation through Src and Syk kinases, but regulates Syk through a novel dimerization mechanism via a single YxxL motif known as a hemITAM. CLEC-2 is a receptor for podoplanin, which is expressed at high levels in several tissues, including type 1 lung alveolar cells, lymphatic endothelial cells, kidney podocytes and some tumors, but is absent from vascular endothelial cells and platelets. In this article, we compare the mechanism of platelet activation by GPVI and CLEC-2 and consider their functional roles in hemostasis and other vascular processes, including maintenance of vascular integrity, angiogenesis and lymphogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345705     DOI: 10.1111/j.1538-7836.2010.03875.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  65 in total

1.  Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development.

Authors:  Kate L Lowe; Brenda A Finney; Carsten Deppermann; René Hägerling; Salomé L Gazit; Jon Frampton; Christopher Buckley; Eric Camerer; Bernhard Nieswandt; Friedemann Kiefer; Steve P Watson
Journal:  Blood       Date:  2015-04-23       Impact factor: 22.113

2.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

Review 3.  Adoptive transfer method to study platelet function in mouse models of disease.

Authors:  Wolfgang Bergmeier; Yacine Boulaftali
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

4.  Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.

Authors:  Bhanu Kanth Manne; Rachit Badolia; Carol Dangelmaier; Johannes A Eble; Wilfried Ellmeier; Mark Kahn; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

5.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

Review 6.  New Concepts and Mechanisms of Platelet Activation Signaling.

Authors:  Brian Estevez; Xiaoping Du
Journal:  Physiology (Bethesda)       Date:  2017-03

7.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Authors:  Phillip L R Nicolson; Craig E Hughes; Stephanie Watson; Sophie H Nock; Alexander T Hardy; Callum N Watson; Samantha J Montague; Hayley Clifford; Aarnoud P Huissoon; Jean-Daniel Malcor; Mark R Thomas; Alice Y Pollitt; Michael G Tomlinson; Guy Pratt; Steve P Watson
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

Review 8.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

9.  Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1.

Authors:  Benjamin E Tourdot; Michelle K Brenner; Kathleen C Keough; Trudy Holyst; Peter J Newman; Debra K Newman
Journal:  Biochemistry       Date:  2013-04-03       Impact factor: 3.162

Review 10.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.